Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/06/068905
CTRI/2024/06/068905
Not yet recruiting
Phase 2

Evaluation of clinical and biochemical outcomes of indocyanine green and methylene blue mediated photodynamic therapy in the non-surgical management of Chronic Periodontitis - A randomized control clinical trial. - NI

Shweta S Patil0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Shweta S Patil
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Shweta S Patil

Eligibility Criteria

Inclusion Criteria

  • •1\.Systemically healthy patients aged 35\-70 yrs. (no history of hypertension, diabetes mellitus, cardiovascular diseases, immunocompromised conditions as well as any condition that could influence the periodontal status).
  • •2\.Patients with no history of antibiotic, anti\-inflammatory drugs, anti\-oxidants and immunosuppressants use for at least 3 months before study.
  • •3\.Patients with moderate chronic periodontitis according to the AAP 1999 Classification (with a probing depth of \=4mm and \=6mm)

Exclusion Criteria

  • •2\.Betel quid or tobacco chewers
  • •3\.Pregnant and lactating women
  • •4\.Patients who underwent any periodontal treatment in last one year

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Study of khadir compound in the management of Kitibha (psoriasis)Health Condition 1: L409- Psoriasis, unspecified
CTRI/2022/02/040085Department of Kayachikitsa Faculty of Ayurveda Institute of Medical Sciences
Not yet recruiting
Not Applicable
EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study
NL-OMON28143Amsterdam University Medical Center30
Active, not recruiting
Phase 1
Evaluation of how well rivaroxaban is absorbed in patients with short bowel syndrom, based on laboratory markers and clinical outcomes such as thrombosis and bleeding.
EUCTR2018-001845-15-NLAcademic medical centre, department of internal medicine30
Recruiting
Phase 4
EvaluaTIoN of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study)short bowel syndrome1002547710014523
NL-OMON48704Vasculaire Geneeskunde30
Not yet recruiting
Not Applicable
Clinical and biochemical profile of AKI in patients with COVID 19. A single center experience.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases
CTRI/2021/03/032067Departmental Funds Depaartment of Medicine SMCW Lavale Pune